Jonelle Hudson, APRN
Adult Health · Boise, IDNPI 1770175614
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,928 of the $5,803 with a category attached, or 84.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 90 payments — averaging $64.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novocure Inc.$970
- Daiichi Sankyo Inc.$415
- Seagen Inc.$376
- AbbVie$281
- Merck$272
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,92885%
- Education$87515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $1,207 |
| Novocure Inc. | 10 | $970 |
| Daiichi Sankyo Inc. | 9 | $415 |
| Seagen Inc. | 4 | $376 |
| AbbVie | 5 | $281 |
| Merck | 6 | $272 |
| Incyte Corporation | 4 | $264 |
| AstraZeneca | 4 | $264 |
| Myriad Genetic Laboratories, Inc. | 2 | $255 |
| Pfizer | 2 | $208 |
| E.r. Squibb & Sons, L.L.C. | 2 | $206 |
| GSK | 3 | $204 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $119 |
| Bristol Myers Squibb | 5 | $113 |
| Exelixis Inc. | 2 | $110 |
| AVEO Pharmaceuticals, Inc. | 1 | $106 |
| Pharmaessentia USA Corporation | 2 | $87 |
| Servier Pharmaceuticals LLC | 1 | $75 |
| Novartis | 3 | $66 |
| Genentech USA, Inc. | 3 | $59 |
| Rigel Pharmaceuticals, Inc. | 1 | $32 |
| Bayer | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Amgen | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,803 in reported general payments places this provider in the 85th percentile of 38 adult health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 11 | $200,393 |
| VenclextaVenetoclax | 11 | $123,282 |
| EliquisApixaban | 37 | $29,022 |
| Anastrozole | 87 | $1,552 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $1,542 |
| Potassium Chloride | 46 | $1,228 |
| Letrozole | 27 | $730 |
| LoperamideLoperamide Hcl | 18 | $622 |
| Morphine Sulfate | 12 | $612 |
| Acyclovir | 25 | $546 |
| Tamoxifen Citrate | 19 | $527 |
| Prochlorperazine Maleate | 23 | $475 |
| Dexamethasone | 30 | $387 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $352 |
| Ondansetron OdtOndansetron | 20 | $337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $206 | $200,39311 claims |
| AbbVieVenclexta | $281 | $123,28211 claims |
| PfizerEliquis | $208 | $29,02237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 38 adult health providers in Idaho.
Other adult health in Boise
- Michelle HicksBoise$40K
- Kaitlin HawsBoise$7K
- Gregory MoranBoise$2K
- Jane SpencerBoise$1K
- Jocelyn McCulloughBoise$1K
- Kristen SantanaBoise$688
- Jessica KeenBoise$406
- Rick BassettBoise$341
- Amanda DraperBoise$265
- Jaclyn ScholtenBoise$223
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.